Olema Pharmaceuticals (OLMA) risk factors, FY2025 10-K

Risks related to our financial position and the need for additional capital

1. 01We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability29% rewritten
2. 02We require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts27% rewritten
3. 03We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long term73% rewritten
4. 04development and other expenses as we continue the clinical development programs for palazestrant in other indications or for OP-3136New
5. 05We have never generated revenue from product sales and may never be profitable
6. 06attracting, hiring and retaining qualified personnel41% rewritten
7. 07The terms of the Loan Agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our businessNew

Risks related to the discovery, development and commercialization of our product candidates

1. 08the approval policies or regulations of the FDA, European Commission, or other comparable foreign regulatory authorities may significantly change in a manner that results in adverse consequences to us, including by rendering our clinical data insufficient for approval
2. 09This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market palazestrant or OP-3136, which would significantly harm our business, financial condition, results of operations, and prospects
3. 10Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales
4. 11third-party contractors not performing data collection or analysis in a timely or accurate manner; or
5. 12Because we are pursuing a variety of target indications for palazestrant and OP-3136, we may expend our limited resources to pursue a particular indication and fail to capitalize on indications or additional product candidates that may be more profitable or for which there is a greater likelihood of success
6. 13Even if approved, palazestrant or OP-3136 may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success
7. 14the approval of other new therapies for the same indications
8. 15If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected
9. 16the level of resources that clinical sites have to conduct a growing number of clinical studies
10. 17We are developing palazestrant and OP-3136 and may develop future product candidates, in combination with other therapies, which exposes us to additional risks33% rewritten
11. 18Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the pre-clinical and clinical development of our drug candidates
12. 19Interim, initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
13. 20We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than palazestrant, OP-3136, or any future product candidates we may develop, our commercial opportunities will be negatively impacted
14. 21Changes in methods of palazestrant and OP-3136 manufacturing or formulation may result in additional costs or delay26% rewritten
15. 22Any product candidate we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations
16. 23Guidelines and recommendations published by various organizations can reduce the use of palazestrant, OP-3136, or any future product candidates we may develop

Risks related to regulatory approval and other legal compliance matters

1. 24We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize palazestrant, OP-3136, or any future product candidates we may develop
2. 25Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability could significantly harm our business, financial condition, results of operations, and prospects
3. 26The FDA, EMA, the European Commission, and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
4. 27Obtaining and maintaining regulatory approval of palazestrant, OP-3136, or any product candidate we develop in the future, in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of palazestrant, OP-3136, or any product candidate we develop in the future, in other jurisdictions
5. 28Even if palazestrant, OP-3136, or any product candidate we develop in the future, receives regulatory approval, it will be subject to significant post-marketing regulatory requirements and oversight
6. 29The occurrence of any event or penalty described above may inhibit our ability to commercialize palazestrant, OP-3136, or any future product candidates we may develop and to generate revenue, could require us to expend significant time and resources in response and could generate negative publicity23% rewritten
7. 30The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses43% rewritten
8. 31reimbursement for the drug until the confirmatory studies are complete. Additionally, if such post-approval studies fail to confirm the drug’s clinical benefit, the FDA may withdraw its approval of the drugNew
9. 32We may face difficulties from changes to current regulations, policies, and future legislation63% rewritten
10. 33If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, our development, approval or commercialization plans may be adversely affected
11. 34analogous state and foreign laws and regulations, such as state and foreign anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers83% rewritten
12. 35Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
13. 36If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business, financial condition, results of operations, or prospects
14. 37Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing

Risks related to employee matters, managing our growth and other risks related to our business

1. 38Unfavorable U.S. and global macroeconomic and geopolitical conditions could adversely affect our business, financial condition, results of operations, and prospects38% rewritten
2. 39International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations, and prospectsNew
3. 40Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees74% rewritten
4. 41In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth25% rewritten
5. 42improving our operational, financial and management controls, reporting systems and procedures
6. 43EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU Member States
7. 44Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
8. 45Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited27% rewritten
9. 46A variety of risks associated with international marketing of palazestrant, OP-3136, or any future product candidates we may develop, if approved, could significantly harm our business, financial condition, results of operations, and prospects

Risks related to our intellectual property

1. 47Our success depends on our ability to protect our intellectual property and our proprietary technologies78% rewritten
2. 48countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates
3. 49If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
4. 50The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad
5. 51Intellectual property rights do not necessarily address all potential threats to our competitive advantage
6. 52Should any of these events occur, it could significantly harm our business, financial condition, results of operations, and prospects62% rewritten
7. 53require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology66% rewritten
8. 54While we may have issued patents that cover palazestrant or OP-3136, it is possible that third parties may have blocking patents that prevent us from marketing, manufacturing or commercializing our own patented products and practicing our own patented technology
9. 55We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time- consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
10. 56Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
11. 57Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
12. 58Changes in patent laws or their interpretations could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our licensors and the enforcement or defense of our issued patents or those of our licensors
13. 59Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect palazestrant, OP-3136, or any future product candidates we may develop
14. 60We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
15. 61Patent terms may be inadequate to protect our competitive position on palazestrant, OP-3136, or any future product candidates we may develop for an adequate amount of time
16. 62In the United States, patent term can be adjusted due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20 years. There is a risk that we may take action that detracts from any accrued patent term adjustment
17. 63If we do not obtain patent term extension for palazestrant, OP-3136, or any future product candidates we may develop, our business, financial condition, results of operations, and prospects may be significantly harmed
18. 64We will not be able to protect our intellectual property rights throughout the world
19. 65Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent authorities, and our patent protection could be reduced or eliminated for non-compliance with these requirements
20. 66If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations, and prospects could be significantly harmed
21. 67If we are unable to protect the confidentiality of our trade secrets, our business, financial condition, results of operations, prospects, and competitive position would be significantly harmed
22. 68We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets
23. 69Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others
24. 70If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
25. 71the priority of invention of patented technology

Risks related to our dependence on third parties

1. 72the misappropriation of our proprietary information, including our trade secrets and know-how58% rewritten
2. 73We have engaged in and may in the future engage in additional acquisitions, strategic partnerships or in-licensing opportunities, that may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
3. 74our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs
4. 75We have third-party collaborators for the development and commercialization of palazestrant. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies
5. 76If we decide to establish collaborations in the future but are not able to establish those collaborations on commercially reasonable terms or at all, we may have to alter our development and commercialization plans

Risks Related to Ownership of Our Common Stock

1. 77An active trading market for our common stock may not be sustained
2. 78The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment32% rewritten
3. 79In addition, the trading prices for common stock of biopharmaceutical companies, including ours, have been highly volatile as a result of factors unrelated to the specific company or its products or products candidates
4. 80Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
5. 81changes in general market and economic conditions
6. 82Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
7. 83Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall29% rewritten
8. 84Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to palazestrant, OP-3136, or future product candidates we may develop on unfavorable terms to us41% rewritten
9. 85New or future changes to tax laws could materially adversely affect our Company28% rewritten
10. 86Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefitsNew
11. 87Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
12. 88require the approval of the holders of at least 66 2⁄3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our amended and restated certificate of incorporations or amended and restated bylaws
13. 89any action asserting a claim against us that is governed by the internal-affairs doctrine or otherwise related to our internal affairs
14. 90We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock
15. 91The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention63% rewritten
16. 92If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
17. 93Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud